ALLMedicine™ Smith-Magenis Syndrome Center
Research & Reviews 76 results
https://www.ncbi.nlm.nih.gov/books/n/gene/sms/
Mar 10th, 2022 - Smith-Magenis syndrome (SMS) is characterized by distinctive physical features (particularly coarse facial features that progress with age), developmental delay, cognitive impairment, behavioral abnormalities, sleep disturbance, and childhood-onse...
https://doi.org/10.1097/YCO.0000000000000790
Current Opinion in Psychiatry; Belli A, Breda M et. al.
Feb 16th, 2022 - In this review we summarized the available evidence on sleep disorders in children with neurodevelopmental disorders (NDDs) in particular: intellectual disability (including some genetic conditions such as Prader-Willi Syndrome, Smith-Magenis Synd...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8815225
Orphanet Journal of Rare Diseases; Agar G, Bissell S et. al.
Feb 6th, 2022 - Smith-Magenis syndrome (SMS) is a rare genetic syndrome associated with a unique profile of early morning waking and daytime sleepiness. Children with SMS evidence high rates of self-injury and aggression and have a preference for adult over peer ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8424817
Orphanet Journal of Rare Diseases; Müller AR, Zinkstok JR et. al.
Sep 10th, 2021 - Smith-Magenis syndrome (SMS) is a rare genetic neurodevelopmental disorder characterized by intellectual disability and severe behavioural and sleep disturbances. Often, patients with SMS are diagnosed with attention-deficit/hyperactivity disorder...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8411507
BMC Medical Genomics; Zhang Y, Liu X et. al.
Sep 3rd, 2021 - Deletion and duplication of the 3.7 Mb region in 17p11.2 result in two syndromes, Smith-Magenis syndrome and Potocki-Lupski syndrome, which are well-known development disorders. The purpose of this study was to determine the prevalence, genetic ch...
Drugs 1 results see all →
Clinicaltrials.gov 2 results
https://clinicaltrials.gov/ct2/show/NCT02231008
May 16th, 2016 - The aim of this study is to investigate tasimelteon vs. placebo on sleep disturbances of individuals with Smith-Magenis Syndrome.
https://clinicaltrials.gov/ct2/show/NCT01903681
Apr 4th, 2014 - There is increasing evidence that chronic sleep disorders in children with autism spectrum disorder (ASD), Angelman Syndrome (AS) and Smith-Magenis syndrome (SMS) are associated with disturbed melatonin secretion and melatonin administration has b...
News 1 results
https://www.medscape.com/viewarticle/907402
Jan 9th, 2019 - In 2018, the European Medicines Agency (EMA) recommended marketing authorization for 84 new medicines, down from 92 in 2017. The 84 medicines given a thumbs up by EMA's Committee for Medicinal Products for Human Use include 42 agents with a new ac...
